WallStSmart

Myomo Inc (MYO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Myomo Inc stock (MYO) is currently trading at $0.70. Myomo Inc PS ratio (Price-to-Sales) is 0.67. Analyst consensus price target for MYO is $4.32. WallStSmart rates MYO as Sell.

  • MYO PE ratio analysis and historical PE chart
  • MYO PS ratio (Price-to-Sales) history and trend
  • MYO intrinsic value — DCF, Graham Number, EPV models
  • MYO stock price prediction 2025 2026 2027 2028 2029 2030
  • MYO fair value vs current price
  • MYO insider transactions and insider buying
  • Is MYO undervalued or overvalued?
  • Myomo Inc financial analysis — revenue, earnings, cash flow
  • MYO Piotroski F-Score and Altman Z-Score
  • MYO analyst price target and Smart Rating
MYO

Myomo Inc

NYSE MKTHEALTHCARE
$0.70
$0.00 (-0.10%)
52W$0.63
$5.39
Target$4.32+520.4%

📊 No data available

Try selecting a different time range

WallStSmart

Smart Analysis

Myomo Inc (MYO) · 8 metrics scored

Smart Score

28
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in price/sales, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.

Myomo Inc (MYO) Key Strengths (2)

Avg Score: 9.0/10
Price/SalesValuation
0.6710/10

Paying less than $1 for every $1 of annual revenue

Institutional Own.Quality
58.58%8/10

58.58% held by institutions, strong professional interest

Supporting Valuation Data

Price/Sales (TTM)
0.668
Undervalued
EV/Revenue
0.692
Undervalued
MYO Target Price
$4.32
426% Upside

Myomo Inc (MYO) Areas to Watch (6)

Avg Score: 1.5/10
Return on EquityProfitability
-86.20%0/10

Company is destroying shareholder value

Operating MarginProfitability
-24.40%0/10

Losing money on operations

Revenue GrowthGrowth
-5.90%0/10

Revenue declining -5.90%, a shrinking business

Profit MarginProfitability
-38.10%0/10

Company is losing money with a negative profit margin

Market CapQuality
$27M3/10

Micro-cap company with very limited liquidity and high volatility

Price/BookValuation
2.406/10

Fairly priced relative to book value

Myomo Inc (MYO) Detailed Analysis Report

Overall Assessment

This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.67) suggest the stock is attractively priced.

The Bear Case

The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Book (2.40) suggest expensive pricing. Growth concerns include Revenue Growth at -5.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -86.20%, Operating Margin at -24.40%, Profit Margin at -38.10%.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -86.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -5.90% needing to reaccelerate.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

MYO Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

MYO's Price-to-Sales ratio of 0.67x sits near its historical average of 0.69x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 0.74x set in Mar 2026, and 3% above its historical low of 0.65x in Mar 2026.

Compare MYO with Competitors

Top MEDICAL DEVICES stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Myomo Inc (MYO) · HEALTHCAREMEDICAL DEVICES

The Big Picture

Myomo Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 41M with 6% decline year-over-year. The company is currently unprofitable, posting a -38.1% profit margin.

Key Findings

Revenue Decline

Revenue contracted 6% YoY. Worth determining whether this is cyclical or structural.

Operating at a Loss

The company is unprofitable with a -38.1% profit margin. The path to breakeven will be the key catalyst.

What to Watch Next

Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Myomo Inc.

Bottom Line

Myomo Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions

Loading insider activity...

About Myomo Inc(MYO)

Exchange

NYSE MKT

Sector

HEALTHCARE

Industry

MEDICAL DEVICES

Country

USA

Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.